These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial. Cağlar N; Dincer I Eur Rev Med Pharmacol Sci; 2011 Dec; 15(12):1359-68. PubMed ID: 22288296 [TBL] [Abstract][Full Text] [Related]
44. Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD). Cadnapaphornchai MA; Fick-Brosnahan GM; Duley I; Johnson AM; Strain JD; DeGroff CG; Schrier RW Contemp Clin Trials; 2005 Apr; 26(2):211-22. PubMed ID: 15837441 [TBL] [Abstract][Full Text] [Related]
45. Twenty-four hour blood pressure profile and left ventricular hypertrophy early after renal transplantation. Marcondes AM; De Lima JJ; Giorgi DM; Vieira ML; de Andrade JL; Ianhez LE; Krieger EM Ren Fail; 2002 Mar; 24(2):207-13. PubMed ID: 12071594 [TBL] [Abstract][Full Text] [Related]
46. Morning rise of blood pressure assessed by home blood pressure monitoring is associated with left ventricular hypertrophy in hypertensive patients receiving long-term antihypertensive medication. Shibuya Y; Ikeda T; Gomi T Hypertens Res; 2007 Oct; 30(10):903-11. PubMed ID: 18049021 [TBL] [Abstract][Full Text] [Related]
47. Morning rise in blood pressure is a predictor of left ventricular hypertrophy in treated hypertensive patients. Ikeda T; Gomi T; Shibuya Y; Matsuo K; Kosugi T; Oku N; Uetake Y; Kinugasa S; Furutera R Hypertens Res; 2004 Dec; 27(12):939-46. PubMed ID: 15894834 [TBL] [Abstract][Full Text] [Related]
48. Comparative renal and cardiac effects of tertatolol and enalapril in essential hypertension. Ribstein J; Du Cailar G; Brouard R; Mimran A Cardiology; 1993; 83 Suppl 1():57-63. PubMed ID: 7903217 [TBL] [Abstract][Full Text] [Related]
49. Tissue Doppler imaging in the evaluation of left ventricular function in young adults with autosomal dominant polycystic kidney disease. Almeida EA; Oliveira EI; Lopes JA; Almeida AG; Prata MM Am J Kidney Dis; 2006 Apr; 47(4):587-92. PubMed ID: 16564936 [TBL] [Abstract][Full Text] [Related]
50. Relationship between home blood pressure and longitudinal changes in target organ damage in treated hypertensive patients. Tsunoda S; Kawano Y; Horio T; Okuda N; Takishita S Hypertens Res; 2002 Mar; 25(2):167-73. PubMed ID: 12047030 [TBL] [Abstract][Full Text] [Related]
51. [The relation of hypertension, renal function and cardiovascular events in autosomal dominant polycystic kidney disease]. Idrizi A; Barbullushi M; Strakosha A; Kodra S; Thereska N; Zaimi E; Gjyzari A; Petrela E G Ital Nefrol; 2007; 24(6):595-9. PubMed ID: 18278763 [TBL] [Abstract][Full Text] [Related]
52. Arterial hypertension increases left ventricular mass: role of tight blood pressure control. Ferrara LA; Vaccaro O; Cardoni O; Mancini M; Zanchetti A J Hum Hypertens; 2004 Sep; 18(9):637-42. PubMed ID: 15014537 [TBL] [Abstract][Full Text] [Related]
53. Hypertension and left ventricular hypertrophy in autosomal dominant polycystic kidney disease. Ecder T; Schrier RW Expert Rev Cardiovasc Ther; 2004 May; 2(3):369-74. PubMed ID: 15151483 [TBL] [Abstract][Full Text] [Related]
54. Isolated ambulatory hypertension and changes in target organ damage in treated hypertensive patients. Cuspidi C; Meani S; Fusi V; Valerio C; Catini E; Magrini F; Zanchetti A J Hum Hypertens; 2005 Jun; 19(6):471-7. PubMed ID: 15744331 [TBL] [Abstract][Full Text] [Related]
55. Left ventricular hypertrophy in nondiabetic predialysis CKD. Paoletti E; Bellino D; Cassottana P; Rolla D; Cannella G Am J Kidney Dis; 2005 Aug; 46(2):320-7. PubMed ID: 16112052 [TBL] [Abstract][Full Text] [Related]
56. Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients. Klingbeil AU; Müller HJ; Delles C; Fleischmann E; Schmieder RE Am J Hypertens; 2000 Dec; 13(12):1295-300. PubMed ID: 11130774 [TBL] [Abstract][Full Text] [Related]
57. Progress in blood pressure control in autosomal dominant polycystic kidney disease. Ecder T; Edelstein CL; Fick-Brosnahan GM; Johnson AM; Duley IT; Gabow PA; Schrier RW Am J Kidney Dis; 2000 Aug; 36(2):266-71. PubMed ID: 10922304 [TBL] [Abstract][Full Text] [Related]
58. Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. Fogari R; Mugellini A; Destro M; Corradi L; Lazzari P; Zoppi A; Preti P; Derosa G Diabet Med; 2012 Jan; 29(1):24-31. PubMed ID: 21781149 [TBL] [Abstract][Full Text] [Related]
59. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Shibasaki Y; Masaki H; Nishiue T; Nishikawa M; Matsubara H; Iwasaka T Nephron; 2002 Mar; 90(3):256-61. PubMed ID: 11867945 [TBL] [Abstract][Full Text] [Related]
60. Hypertension and renal injury in experimental polycystic kidney disease. Kennefick TM; Al-Nimri MA; Oyama TT; Thompson MM; Kelly FJ; Chapman JG; Anderson S Kidney Int; 1999 Dec; 56(6):2181-90. PubMed ID: 10594794 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]